SETD2 and nonpapillary renal cell carcinoma: To do this, we challenged SETD2 proficient and SETD2 deficient ccRCC-derived cell lines with the AKT-specific inhibitor MK2206 and observed their sensitivity to the compound, spheroid formation, and migration.